Tecan Group Ltd. Q2 2026 Earnings Recap

Shares fell 9.7% as investors marked down the stock on cautious outlook signals and disappointing margin and EPS trends, despite reported above-market sales growth. The apparent disconnect stems from adjusted EPS declining notably and indications that growth is uneven and sensitive to customer concentration.

Key Takeaways

• Group sales grew 3.4% in local currency to CHF 427.5 million, with order entry up 3%, keeping book-to-bill above 1 in both segments.
• Adjusted EBITDA margin held relatively flat at 15.1%, but profitability was weighed down by Rewired transformation costs and IT investments.
• Adjusted EPS decreased to CHF 2.62 from last year’s higher level, reflecting FX headwinds and margin pressure.
• Life Sciences grew 3.1% in local currency, driven by Biopharma and Diagnostics, however, Academia and Government sales declined double digits.
• Growth concentrated in Asia and specific customers, with Europe stable and the U.S. delivering minimal growth, heightening revenue volatility risk.